StockNews.AI · 3 hours
Select Medical announced the completion of its merger with a consortium led by Ortenzio and WCAS, with the deal closing on July 1, 2026. Shareholders receive $16.50 per share, valuing the company at ~$3.9B and signaling a premium to prior levels. SEM will delist, transfer control to the private equity group, and leadership will largely remain in place, implying limited public-market upside from here.
The take-private completion fixes the equity value at $16.50 and results in delisting; immediate price discovery is limited to the announced price, with no ongoing public-market upside or volatility once closed.
Take-private closure ends SEM public trading; immediate cash-out at $16.50 with no further equity upside.
Category: M&A. The article reports the completion of a structured take-private transaction, a classic corporate-developments event with material implications for valuation, liquidity, and ownership as SEM transitions from a public to a private entity under private-equity control.